Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Phase 2a Trial Topline Results Expected in Third Quarter 2025. The Company expects to announce topline results for its Phase 2a trial in patients with refractory focal epilepsy in the third quarter of ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...

Independent directors Sarah Hofstetter, Erica Mann, and Jeffrey Smith join the Board.

The disclosure of a new candidate by Dewpoint Therapeutics Inc. was the latest in the percolating beta-catenin/Wnt space, where a handful of firms have been making progress.

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...

As the contentious debate over compounded weight loss drugs continues, Eli Lilly is stepping out with an ad campaign to further stake its claim as a leader in the obesity market. In the national print ...